New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...

Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

1. Willi R, Bril V, Howard J, et al. RELIEVE: a phase 3 study evaluating the efficacy and safety of remibrutinb in generalized myasthenia gravis. Presented at: American Association of Neuromuscular & ...

Beyond the 4-week mark, both MG-ADL and Quantitative Myasthenia Gravis scores improved in the overall population and in all ...

The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...

What are called autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most ...

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...